Biotechnology Companies with Great Potential

LAS VEGAS, March 16, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

According to a new report by Global Market Insights, Inc. the Biotech Market size will reach USD 775.20 billion by 2024 at a CAGR of 9.9%.

Rising prevalence of chronic diseases have increased the demand for innovation, similar to DNA sequencing, micro-assays and recombinant DNA technologies to develop therapeutic solutions. Government support for R&D has accelerated development of products and vaccines for such chronic ailments. Included in today's commentary: Propanc Biopharma, Inc. (OTC: PPCB), Gilead, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN), Biogen, Inc. (NASDAQ: BIIB), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), and Seattle Genetics

Strong R&D spending trends for synthetic biology, involving large scale manipulation of DNA sequences to enable drug and vaccine development, including Europe's NEST (New and Emerging Synthetic Technology) program, will stimulate growth. Organizations including DBT (Department of Biotechnology) and NTBT (National Biotechnology Board) provide funding to promote biotechnology market share. BioBricks, a non-profit organization delivers synthetic biology technologies for humanitarian purposes. Similarly, synthetic forum OpenWetWater offers conceptual training to researchers.

U.S. biotechnology market size held dominant position in terms of industry revenue share followed by Europe with this trend likely to continue throughout the forecast period. U.S. will further see increased adoption of products based on these platforms due to growing preference for personalized medicine.

India, China, Brazil hold excellent business growth opportunities due to large population base, increase in per capita income, better health care facilities, increasing government aid to promote biotechnology market share.

A few biotech companies in the news that could benefit include: Propanc Biopharma, Inc. (OTCQB: PPCB), Gilead, Inc. (NASDAQ: GILD), Amgen, Inc. (NASDAQ: AMGN), Biogen, Inc. (NASDAQ: BIIB), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), and Seattle Genetics.

Propanc Biopharma, Inc. (OTCQB: PPCB)

Market Cap: 2.03M, current share price: $.096 

PPCB, a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, recently announced allowance of a key patent application from the European Patent Office (EPO) covering a pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen within the European Union. The allowed patent application is the first approval for the Company in the EU, which protects the Company's lead product candidate, PRP, a solution for once-daily intravenous administration of a combination of two pancreatic proenzymes trypsinogen and chymotrypsinogen.